Kinneret Savitsky - BioLineRx CEO
| BLRX Stock | USD 0.68 0.02 3.03% |
CEO
Dr. Kinneret Savitsky will no longer serve as Chief Executive Officer at BioLine Rx Ltd effective October 10 2016. She has held this role since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers since 2010.
| Age | 48 |
| Tenure | 14 years |
| Address | Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 |
| Phone | 972 8 642 9100 |
| Web | https://www.biolinerx.com |
BioLineRx Management Efficiency
The company has return on total asset (ROA) of (0.383) % which means that it has lost $0.383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8923) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.23 in 2024. Debt To Assets is likely to rise to 0.17 in 2024, whereas Total Assets are likely to drop slightly above 53.7 M in 2024.Similar Executives
| Showing other executives | CEO Age | ||
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Todd MA | Arcutis BiotherapeuticsInc | 56 | |
| Dror Bashan | Protalix Biotherapeutics | 57 | |
| Richard Adcock | Immunitybio | 55 | |
| Eric MBA | Seres Therapeutics | 48 | |
| Moshe Manor | Protalix Biotherapeutics | 61 | |
| Ted White | Verrica Pharmaceuticals | 59 | |
| Mel MD | Galera Therapeutics | 67 | |
| Lonnel Coats | Lexicon Pharmaceuticals | 59 | |
| Manuel MD | Mustang Bio | 70 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Sven Karlsson | Verona Pharma PLC | 59 | |
| David PharmD | Verona Pharma PLC | 60 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Michael Raab | Ardelyx | 59 | |
Management Performance
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.38 |
BioLineRx Leadership Team
Elected by the shareholders, the BioLineRx's board of directors comprises two types of representatives: BioLineRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLineRx. The board's role is to monitor BioLineRx's management team and ensure that shareholders' interests are well served. BioLineRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLineRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ella Sorani, Vice President-Development | ||
| Adam Esq, General Compliance | ||
| Leah Klapper, Consultant | ||
| Avraham Molcho, External Director | ||
| CPA MBA, Chief Officer | ||
| Moshe Phillip, Vice President of Medical Affairs and Senior Clinical Advisor | ||
| Aharon Schwartz, Chairman of the Board | ||
| Mali Zeevi, Finance Director | ||
| Arnon Aharon, Vice President-Medical Affairs | ||
| Merril Gersten, Chief Scientific Officer | ||
| Holly MBA, President USA | ||
| Michael Anghel, Director | ||
| Raphael Hofstein, Director | ||
| CPA CPA, Chief Officer | ||
| Raziel Fried, Treasurer Director | ||
| Sandra Panem, Director | ||
| Philip Serlin, CFO, COO | ||
| Advocate Kotler, Gen Officer | ||
| John Lacey, Head Relations | ||
| Abi MD, Chief Officer | ||
| LLB BSc, Head Advisor | ||
| Abi VainsteinHaras, Vice President-Clinical & Medical Affairs | ||
| Jacob Friedman, Director | ||
| BarbaraJean Bormann, Director | ||
| Kinneret Savitsky, CEO | ||
| Jael MSc, QA RA | ||
| Liron MBA, Director Devel | ||
| David Malek, Vice President - Business Development | ||
| Nurit Benjamini, External Director |
BioLineRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLineRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (2.47) % | ||||
| Current Valuation | 681.94 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Shares Owned By Insiders | 8.54 % | ||||
| Shares Owned By Institutions | 1.43 % | ||||
| Number Of Shares Shorted | 591.45 K | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 4.33 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioLineRx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioLineRx's short interest history, or implied volatility extrapolated from BioLineRx options trading.
Pair Trading with BioLineRx
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioLineRx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioLineRx will appreciate offsetting losses from the drop in the long position's value.Moving together with BioLineRx Stock
| 0.87 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against BioLineRx Stock
| 0.63 | ELYM | Eliem Therapeutics | PairCorr |
| 0.49 | OPT | Opthea | PairCorr |
| 0.45 | MRK | Merck Company Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to BioLineRx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioLineRx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioLineRx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioLineRx to buy it.
The correlation of BioLineRx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioLineRx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioLineRx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioLineRx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for BioLineRx Stock analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is BioLineRx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.075 | Return On Assets (0.38) | Return On Equity (1.89) |
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.